Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Global study tracks how COVID-19 variants outsmart vaccines

NCT ID NCT05534009

Knowledge-focused Sponsor: Euresist Network GEIE Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study follows 1800 healthcare workers from eight countries for up to 24 months to see how their immune systems respond to COVID-19 vaccines and infections. Researchers will collect blood samples and health data to understand how different viral variants affect immunity. The goal is to improve future vaccine strategies, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help scientists understand how well vaccines and past infections protect against new COVID-19 variants.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly lead to a new therapy. Results may take time and might not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

For each subject baseline will be the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. Health CareWorkers can be enrolled in the category of: (i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection. However, infections diagnosed during the first wave of the epidemic are suitable for the analysis of natural immunity to SARS-CoV-2 because vaccination was administered several months later.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The study subjects will be selected based on the following inclusion criteria: 1. Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. 2. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA 3. Having a signed informed consent when required by ethical approval Exclusion Criteria: NONE

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo

    RECRUITING

    Milan, Italy

  • Bach Mai Hospital

    RECRUITING

    Hanoi, Vietnam

  • Centro Hospitalar de Lisboa Ocidental

    RECRUITING

    Lisbon, Portugal

  • Heinrich Heine university

    RECRUITING

    Düsseldorf, Germany

  • Hospital Juan Ghaham Casasus

    RECRUITING

    Villahermosa, Mexico

  • Ieo Istituto Europeo Di Oncologia

    RECRUITING

    Milan, Italy

  • Viesoji Istaiga Vilniaus Uiversiteto Ligoninė Santaros klinikos

    RECRUITING

    Vilnius, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.